New pancreatic cancer pill nearly doubles survival time in breakthrough trial

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. Mutual Fund and ETF data provided by LSEG. Family and emergency medicine physician Dr. Janette Nesheiwat discusses how artificial intelligence could help detect pancreatic cancer earlier and the FDA fast-tracking the drug daraxonrasib on ‘Fox Report.’ A new drug for pancreatic cancer is showing promise in early testing. Daraxonrasib is a daily pill designed to block cancer signals linked to the RAS gene. It has now finished an early-stage clinical trial — the first time it was tested in people — to evaluate both its safety and effectiveness. The final drug analysis, following phase 3 trial results, was presented on Sunday during the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. 6 THINGS TO KNOW ABOUT PANCREATIC CANCER AFTER FORMER SENATOR’S DIAGNOSIS The RASolute 302 trial, involving 500 patients previously treated for metastatic pancreatic cancer, revealed that dail

May 18, 2026 → Jun 2, 2026